Fundraising Fox5AM Ventures — 2015 Investments
8 investments dated 2015 · listed companies and verified rows first · show all
Pulmatrix develops inhaled dry-powder therapies using its proprietary iSPERSE technology, which uses small, dense, dispersible particles to deliver respiratory and non-respiratory drugs via the respiratory system.
BiotechDeep TechHealthtechMedical DevicesFramingham, US
Anand Varadan(Director)inRichard Batycky(Director)Peter Ludlum(Interim Chief Executive Officer)Hojabr Alimi(Executive Officer)Sameer Harish(Executive Officer)
BoardRichard Conley(Director)
Board seatScott M. Rocklage· per SEC Form D
Co-investorsALTITUDE LIFE SCIENCE VENTURESARCH Venture PartnersPolaris Partners
Pharmaceutical company developing medicines and vaccines for patient health and treatment.
BiotechHealthtechSan Diego, US
Jeffrey Stein(Executive Officer, Director)Kevin Judice(Director)inKevin Forrest(Executive Officer)Dirk Thye(Executive Officer)inKen Bartizal(Executive Officer)inPaul Daruwala(Executive Officer)in
Board seatScott M. Rocklage· per SEC Form D
Co-investorsAisling CapitalBain Capital Life SciencesFrazier Life SciencesRA CapitalVivo CapitalCanaan Partners+1 more
Develops tools to formulate and manufacture nanoparticles used as medicines; acquired by Danaher in 2021.
BiotechVancouver
Euan Ramsay(Executive Officer)inJames Taylor(Founder)inAndrew Booth(Director)R. James Taylor(Executive Officer, Director)Joe Victor(Executive Officer, Director)Daniel Nixon(Director)
Board seatAndrew J. Schwab· per SEC Form D · $13.4M raise · filed Nov 2016
Co-investorsBDC Industrial Innovation Venture FundInnovative Solutions CanadaPage One VenturesRising TideTelegraph Hill Partners
BiotechResearch Triangle Park, US
Andrew Jordan(Executive Officer, Director)John Taylor(Executive Officer, Director, Promoter)Robert Tarran(Director)
BoardDonald Rose(Director)
Board seatBrian Daniels· per SEC Form D
Co-investorsCanaan PartnersHatteras Venture Partners
VBI Vaccines is a biopharmaceutical company developing vaccine candidates using virus-like particle (VLP) platforms, including proprietary enveloped VLP and mRNA-launched eVLP technologies.
BiotechHealthtechCambridge, US
Marc Kirchmeier(Vice President, Formulation Development)Egidio Nascimento(Chief Financial Officer)inDavid Anderson(Senior Vice President, Research)inJeff Baxter(President and Chief Executive Officer)inAdam T. Buckley(Vice President, Business Development)inMurray G. Smith(Executive Officer)
Co-investorsARCH Venture PartnersClarus VenturesK2 HealthVentures
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Igenica BiotherapeuticsKinestral TechnologiesPulmatrix Operating
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.